Drs. Mease, Siegel, Cohen, and Ory have received consulting fees and honoraria from Amgen. Drs. Mease, Kivitz, and Siegel have stock ownership or options in Amgen. Drs. Ory, Salonen, Rubenstein, and Sharp were compensated for reading radiographs in this study.
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression†
Article first published online: 6 JUL 2004
Copyright © 2004 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 50, Issue 7, pages 2264–2272, July 2004
How to Cite
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T. and Tsuji, W. (2004), Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis & Rheumatism, 50: 2264–2272. doi: 10.1002/art.20335
- Issue published online: 6 JUL 2004
- Article first published online: 6 JUL 2004
- Manuscript Accepted: 16 MAR 2004
- Manuscript Received: 11 SEP 2003
- Immunex Corporation, a wholly owned subsidiary of Amgen, Inc.
Etanercept has been shown to improve the articular and cutaneous manifestations of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA.
Patients with PsA (n = 205) were randomized to receive placebo or 25 mg etanercept subcutaneously twice weekly for 24 weeks. Patients continued to receive blind-labeled therapy in a maintenance phase until all had completed the 24-week phase, then could receive open-label etanercept in a 48-week extension. Efficacy and safety were evaluated at 4, 12, and 24 weeks and at 12-week intervals thereafter. Radiographs of the hands and wrists were assessed at baseline and 24 weeks, at entry to the open-label phase, and after 48 weeks in the study.
Etanercept significantly reduced the signs and symptoms of PsA and psoriasis. At 12 weeks, 59% of etanercept patients met the American College of Rheumatology 20% improvement criteria for joint response, compared with 15% of placebo patients (P < 0.0001), and results were sustained at 24 and 48 weeks. At 24 weeks, 23% of etanercept patients eligible for psoriasis evaluation achieved at least 75% improvement in the Psoriasis Area and Severity Index, compared with 3% of placebo patients (P = 0.001). Radiographic disease progression was inhibited in the etanercept group at 12 months; the mean annualized rate of change in the modified total Sharp score was −0.03 unit, compared with +1.00 unit in the placebo group (P = 0.0001). Etanercept was well tolerated.
Etanercept reduced joint symptoms, improved psoriatic lesions, inhibited radiographic progression, and was well tolerated in patients with PsA.